Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial

INTRODUCTION: The PIONEER 7 trial demonstrated superior glycemic control and weight loss with once-daily oral semaglutide with flexible dose adjustment versus sitagliptin 100 mg in type 2 diabetes. This 52-week extension evaluated long-term oral semaglutide treatment and switching from sitagliptin t...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMJ Open Diabetes Res Care
Auteurs principaux: Buse, John B, Bode, Bruce W, Mertens, Ann, Cho, Young Min, Christiansen, Erik, Hertz, Christin L, Nielsen, Morten A, Pieber, Thomas R
Format: Artigo
Langue:Inglês
Publié: BMJ Publishing Group 2020
Sujets:
Emerging Technologies, Pharmacology and Therapeutics
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7737050/
https://ncbi.nlm.nih.gov/pubmed/33318068
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjdrc-2020-001649
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires